

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number  
**WO 2004/011632 A2**

(51) International Patent Classification: **C12N 5/06**  
(21) International Application Number:  
PCT/CA2003/001151

(22) International Filing Date: 30 July 2003 (30.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/399,192 30 July 2002 (30.07.2002) US

(71) Applicant (for all designated States except US): **STEM CELL THERAPEUTICS INC.** [CA/CA]; 415 Yonge Street, Suite 1103, Toronto, Ontario M5B 2E7 (CA).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **WEISS, Samuel** [CA/CA]; 4540 Chapel Road, N.W., Calgary, Alberta T2L 1A6 (CA).

(74) Agents: **TORYS LLP** et al.; Maritime Life Tower, Suite 3000, 79 Wellington St. W., Box 270, TD Centre, Toronto, Ontario M5K 1N2 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)


— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

#### Published:

— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: OLIGODENDROCYTE PRODUCTION FROM MULTIPOTENT NEURAL STEM CELLS



(57) Abstract: This invention relates to methods of producing oligodendrocytes from multipotent neural stem cells by using at least one oligodendrocyte promoting factor, particularly granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin 3 or interleukin 5. The neural stem cells may optionally be expanded prior to being subjected to the oligodendrocyte promoting factor.

WO 2004/011632 A2



---

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**OLIGODENDROCYTE PRODUCTION FROM MULTIPOTENT  
NEURAL STEM CELLS**

5

**RELATED APPLICATIONS**

This application claims the benefit of U.S. Provisional Application Serial Number 60/399,192, the entire disclosure of which is hereby incorporated by reference.

10

**FIELD OF THE INVENTION**

This invention relates to methods of producing oligodendrocytes by using an oligodendrocyte promoting factor, particularly granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin 3 or interleukin 5.

15

**REFERENCES**

20

U.S. Patent No. 5,128,242.

U.S. Patent No. 5,198,542.

U.S. Patent No. 5,208,320.

25

U.S. Patent No. 5,326,860.

U.S. Patent No. 5,547,935.

30

U.S. Patent No. 5,623,050.

U.S. Patent No. 5,750,376.

U.S. Patent No. 5,801,147.

U.S. Patent No. 5,851,832.

5 U.S. Patent No. 5,955,346.

U.S. Patent No. 5,980,885.

10 U.S. Patent No. 6,191,106.

U.S. Patent No. 6,242,563.

U.S. Patent No. 6,429,186.

15 WO 03/040310. Be'eri H et al. The cytokine network of wallerian degeneration: IL-10 and GM-CSF. Eur. J. Neurosci. 10(8):2707-13 (1998).

20 Bernichtein, S., et al. S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist. Endocrinology 142(9):3950-3963 (2001).

Brierley CM et al. Remyelination of demyelinated CNS axons by transplanted human schwann cells: the deleterious effect of contaminating fibroblasts. Cell Transplant. 10(3):305-15 (2001).

25 Kohama I et al. Transplantation of cryopreserved adult human Schwann cells enhances axonal conduction in demyelinated spinal cord. J. Neurosci. 21(3):944-50 (2001).

30 Learish RD et al. Intraventricular transplantation of oligodendrocyte progenitors into a fetal myelin mutant results in widespread formation of myelin. Ann. Neurol. 46(5):716-722 (1999).

McLay RN et al. Granulocyte-macrophage colony-stimulating factor crosses the blood-brain and blood-spinal cord barriers. Brain 120:2083-2091 (1997).

Miller RH. Regulation of oligodendrocyte development in the vertebrate CNS. Progress in Neurobiology 67: 451-467 (2002).

- 5           Ousman SS et al. MIP-1alpha, MCP-1, GM-CSF, and TNF-alpha control the immune cell response that mediates rapid phagocytosis of myelin from the adult mouse spinal cord. J. Neurosci. 21(13):4649-4656 (2001).

- Raff MC. Glial cell diversification in the rat optic nerve. Science  
10   243(4897):1450-5 (1989).

          Smith PM and Franklin RJ. The effect of immunosuppressive protocols on spontaneous CNS remyelination following toxin-induced demyelination. J. Neuroimmunol. 119(2):261-8 (2001).

15

          All of the publications, patents and patent applications cited in this application are herein incorporated by reference in their entirety to the same extent as if the disclosure of each individual publication, patent application or patent was specifically and individually indicated to be incorporated by reference in its entirety.

20

## BACKGROUND OF THE INVENTION

The axons of many vertebrate neurons are insulated by a myelin sheath, which greatly increases the rate at which axons can conduct an action potential. Myelin is a cellular sheath formed by special glial cells, namely Schwann cells in the peripheral nervous system and oligodendrocytes in the central nervous system. These glial cells wrap layer upon layer around the axon in a tight spiral, thereby insulating the axonal membrane. However, the sheath is interrupted at regularly spaced nodes of Ranvier, where membrane depolarization can occur. As a result, depolarization of the membrane at one node immediately spreads to the next node. Thus, an action potential propagates along a myelinated axon by jumping from node to node, thereby accelerating transmission of the signal as well as conserving metabolic energy, since the active excitation is confined to the small regions of axonal plasma membrane at the nodes.

The importance of myelination is evidenced by demyelinating diseases such as multiple sclerosis, in which myelin sheaths in some regions of the central nervous system are destroyed by an unknown mechanism. When demyelination occurs, the propagation of nerve impulses is significantly slowed, leading to devastating neurological consequences. For example, common symptoms of multiple sclerosis include muscular weakness, slow movements, spasticity, severe fatigue or even disabling exhaustion, visual disturbances, pain, numbness, tingling, urinary dysfunction, sexual dysfunction and mental disturbances.

Current treatments of multiple sclerosis involve slowing down the disease course as well as alleviation of the symptoms or medical complications, rather than addressing the underlying cause of the disease, demyelination. However, ample evidence indicates that demyelinated neurons are capable of remyelination *in situ*. In multiple sclerosis, it appears that cycles of demyelination and remyelination take place, and glial cell transplantation has been investigated as a potential therapy (see, e.g., Smith et al., 2001; Brierley et al., 2001; Kohama et al., 2001). Nevertheless, obtaining large numbers of myelinating cells for transplantation remains a major stumbling block. Glial progenitor cells are available for transplantation; for example, O-2A cells give rise *in vitro* to oligodendrocytes and type II astrocytes. Although O-2A cells can be grown in culture, only a limited number of divisions are possible (Raff, 1989). Moreover, it appears that the O-2A cells that have been

injected into animals do not continue to divide, and a large number of cells have to be transplanted. Therefore, an improved source of transplant for remyelination is desirable.

## SUMMARY OF THE INVENTION

The present invention relates to methods of producing oligodendrocytes from multipotent neural stem cells by using an oligodendrocyte promoting factor, particularly  
5 granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), interleukin 3 (IL-3) or interleukin 5 (IL-5). We demonstrate herein that these factors, such as GM-CSF, significantly increased the percentage of oligodendrocytes produced from neural stem cells. When GM-CSF was present in the proliferation media of neural stem cells, proliferating neural stem cells were decreased  
10 while oligodendrocytes were increased. Therefore, GM-CSF can shift fate determination of neural stem cells toward the oligodendrocyte lineage. To maximize oligodendrocyte production, it is preferable to enhance neural stem cell proliferation first, followed by subjecting the expanded neural stem cells to the oligodendrocyte promoting factor to increase oligodendrocyte formation.

15

The present invention further provides a method of producing oligodendrocytes *in vivo* by administering at least one oligodendrocyte promoting factor to a mammal. This method can be used to enhance myelination, particularly remyelination in a mammal with a demyelinating disease. Accordingly, the present invention also provides a method of  
20 treating or ameliorating a demyelinating disease by using an oligodendrocyte promoting factor.

Accordingly, one aspect of the present invention provides a method of producing oligodendrocytes from mammalian multipotent neural stem cells, comprising contacting  
25 multipotent neural stem cells with an effective amount of at least one oligodendrocyte promoting factor under conditions that result in production of oligodendrocytes from the multipotent neural stem cells. The oligodendrocyte promoting factor is preferably selected from the group consisting of GM-CSF, G-CSF, IL-3 and IL-5. The oligodendrocyte promoting factor is more preferably GM-CSF or G-CSF, and is most preferably GM-CSF.

30

The neural stem cells can be any mammalian neural stem cells, including, for example, human, feline, canine, rodent, sheep, goat, cattle, horse, pig, and non-human primate cells. The neural stem cells are preferably human cells.



The method can be practiced *in vitro* or *in vivo*. For the *in vitro* method, the neural stem cells may be provided as a cell culture, and the oligodendrocyte promoting factor can be included in the culture medium. The culture is preferably prepared by using mammalian brain tissue obtained from any mammal, including embryonic, neonatal and adult mammals. In particular, the brain tissue is obtained from a non-embryonic mammal, preferably an adult mammal. The brain tissue is preferably the subventricular zone in the forebrain.

For the *in vivo* method, the neural stem cells are located in a mammal, particularly in the subventricular zone. The mammal preferably harbors a demyelinating disease, such as a disease selected from the group consisting of multiple sclerosis, acute disseminated encephalomyelitis, diffuse cerebral sclerosis, necrotizing hemorrhagic encephalitis and leukodystrophies. The disease is preferably multiple sclerosis.

Optionally, the neural stem cells are also subjected to at least one biological agent that is capable of increasing the number of multipotent neural stem cells. The biological agent is preferably selected from the group consisting of epidermal growth factor (EGF), pituitary adenylate cyclase-activating polypeptide (PACAP), fibroblast growth factor (FGF), transforming growth factor  $\gamma$  (TGF $\gamma$ ), ciliary neurotrophic factor (CNTF), estrogen, ovarian hormone, prolactin, growth hormone, and insulin-like growth factor 1. The neural stem cells are preferably contacted by the biological agent first to increase the number of neural stem cells before being subjected to the oligodendrocyte promoting factor. Alternatively, the neural stem cells may be contacted by the biological agent and the oligodendrocyte promoting factor concurrently.

Furthermore, others factors that promote oligodendrocyte differentiation, growth, proliferation or survival can also be used in combination with the oligodendrocyte promoting factor. A preferred example of such other factors is triiodothyronine.

Another aspect of the present invention provides a composition comprising the oligodendrocytes produced from neural stem cells by using at least one oligodendrocyte promoting factor. The composition may optionally comprise a pharmaceutically acceptable

excipient and/or a pharmaceutically acceptable carrier to form a pharmaceutical composition.

- Also provided is a method of providing oligodendrocytes to a mammal,
- 5 comprising
- (a) introducing multipotent neural stem cells into the mammal and administering an effective amount of at least one oligodendrocyte promoting factor to the mammal under conditions that result in oligodendrocyte formation from the neural stem cells; or
  - 10 (b) introducing into the mammal an effective amount of the pharmaceutical composition described above.

When method (a) is employed, the neural stem cells can be further contacted, either prior to the introduction or after the introduction occurs, by at least one biological agent that is capable of increasing the number of neural stem cells. It is also contemplated that the biological agent can be used both before and after transplantation. The agent can be added to the culture media before transplantation and/or administered to the mammal after transplantation.

- 20 Another aspect of the present invention provides a method of treating or ameliorating a demyelinating disease in a mammal, comprising administering to the mammal an effective amount of at least one oligodendrocyte promoting factor. The mammal preferably harbors a demyelinating disease, such as a disease selected from the group consisting of multiple sclerosis, acute disseminated encephalomyelitis, diffuse cerebral sclerosis, necrotizing hemorrhagic encephalitis and leukodystrophies. The disease is preferably multiple sclerosis. The mammal may additionally receive at least one biological agent that is capable of increasing the number of neural stem cells, and/or at least one factor that is known to stimulate oligodendrocyte differentiation, growth, proliferation or survival. The oligodendrocyte promoting factor, the biological agent, and/or other factors
- 25 can be administered in any manner that results in contact of the factor and/or agent with multipotent neural stem cells in the mammal, such as systemically (e.g., subcutaneously) or *in situ* (e.g., administered into the brain, particularly a lateral ventricle of the brain).
- 30

## BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1.** A soluble GM-CSF receptor (sGMRV) inhibits the effects of GM-CSF. DIV: days *in vitro*. \*  $p < 0.001$ . The experiments were repeated 4 times (N=4).

5

**Figure 2.** The percent of dying maturing oligodendrocytes. C: control; GM: GM-CSF; T3: triiodothyronine; DIV: days *in vitro*. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ . The experiments were repeated 4 times (N=4).

10 **Figure 3.** The effects of GM-CSF (G) and T3 (T) on total cell numbers of primary neural stem cell culture. E+G: EGF+GM-CSF; E+T: EGF+T3. \*  $p < 0.05$ , \*\*  $p < 0.001$ . The experiments were carried out 4 times (N=4).

15 **Figure 4.** Primary neurosphere numbers when cultured in various media. E+G: EGF+GM-CSF; E+T: EGF+T3.

20 **Figure 5.** Secondary neurosphere numbers when cultured in various media. 1<sup>o</sup>: primary neurosphere media; P1: secondary neurosphere media; E: EGF; E+G: EGF+GM-CSF; E+T: EGF+T3. \*  $p < 0.001$ . The experiments were performed 5 times (N=5).

**Figure 6.** Fate determination analysis. Mature oligodendrocytes (MBP+ cells) or neurons ( $\beta$ -tubulin+ cells) were counted after neural stem cells had been cultured in various media. E: EGF; E+G: EGF+GM-CSF; E+T: EGF+T3. \*  $p < 0.05$ .

25

## DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to methods of producing oligodendrocytes from multipotent neural stem cells by using at least one oligodendrocyte promoting factor, particularly granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), interleukin 3 (IL-3) or interleukin 5 (IL-5). We demonstrate herein that GM-CSF significantly increased the percentage of oligodendrocytes produced from neural stem cells. When GM-CSF was present in the

30

proliferation media of neural stem cells, proliferating neural stem cells were decreased while oligodendrocytes were increased. Therefore, GM-CSF can shift fate determination of neural stem cells toward the oligodendrocyte lineage. To maximize oligodendrocyte production, it is preferable to enhance neural stem cell proliferation first, followed by  
5     subjecting the expanded neural stem cells to the oligodendrocyte promoting factor to increase oligodendrocyte formation.

The present invention further provides a method of producing oligodendrocytes *in vivo* by administering at least one oligodendrocyte promoting factor to a mammal. This  
10     method can be used to enhance myelination, particularly remyelination in a mammal with a demyelinating disease. Accordingly, the present invention also provides a method of treating or ameliorating a demyelinating disease by using at least one oligodendrocyte promoting factor.

15     Prior to describing the invention in further detail, the terms used in this application are defined as follows unless otherwise indicated.

#### Definitions

20     A "multipotent neural stem cell", or "neural stem cell", is a stem cell in the neural cell lineage. A stem cell is a cell which is capable of reproducing itself. In other words, when a stem cell divides, at least some of the resulting daughter cells are also stem cells. Neural stem cells and their progeny are capable of differentiating into all the cell types in the neural cell lineage, including neurons, astrocytes and oligodendrocytes (astrocytes and  
25     oligodendrocytes are collectively called glia or glial cells). Therefore, the neural stem cells are multipotent neural stem cells. Multipotent neural stem cells are described, for example, in U.S. Patent Nos. 5,750,376; 5,980,885; and 5,851,832.

The adult neural stem cells preferably refer to the neural stem cells located in or  
30     derived from the subventricular zone (SVZ) of the forebrain of adult mammals, which are different from the proliferating cells in the adult hippocampus.

The "progeny" of neural stem cells described herein refers to any and all cells derived from neural stem cells as a result of proliferation or differentiation.

5 A "neurosphere" is a group of cells derived from a single neural stem cell as the result of clonal expansion. Primary neurospheres are generated by plating as primary cultures brain tissue which contains neural stem cells. The method for culturing neural stem cells to form neurospheres has been described in, *e.g.*, U.S. Patent No. 5,750,376. Secondary neurospheres can be generated by dissociating primary neurospheres and allowing the individual dissociated cells to form neurospheres again.

10

An "oligodendrocyte promoting factor" is a substance that is capable of increasing oligodendrocyte formation from multipotent neural stem cells. The oligodendrocyte promoting factor is preferably selected from the group consisting of granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), interleukin 3 (IL-3) and interleukin 5 (IL-5).

15

A "granulocyte-macrophage colony stimulating factor", or "GM-CSF" is a protein factor which (1) shares substantial sequence identity with the native human GM-CSF; and (2) possesses a biological activity of the native human GM-CSF.

20

A protein which shares "substantial sequence identity" with a native mammalian protein consists of at least one polypeptide that is at least about 30% identical with the native mammalian protein at the amino acid level. The protein is preferably at least about 40%, more preferably at least about 60%, yet more preferably at least about 70%, and most preferably at least about 80% identical with the native protein at the amino acid level. Thus, the protein is a variant or analog of the native protein. For example, a protein that shares a substantial sequence identity with the native human GM-CSF consists of at least one polypeptide that is at least about 30% identical with the native human GM-CSF at the amino acid level. The protein is preferably at least about 40%, more preferably at least about 60%, yet more preferably at least about 70%, and most preferably at least about 80% identical with the native human GM-CSF at the amino acid level. Thus, the term "GM-CSF" encompasses GM-CSF analogs which are the deletional, insertional, or substitutional mutants of the native GM-CSF. Furthermore, the term "GM-CSF" encompasses the GM-

25

30

CSFs from other species, the naturally occurring variants, and different post-translationally modified forms (such as the glycosylated and phosphorylated forms) thereof.

5 The phrase "percent identity" or "% identity" with a native protein refers to the percentage of amino acid sequence in the native protein which are also found in the variant or analog when the two sequences are best aligned (including gaps). Percent identity can be determined by any methods or algorithms established in the art, such as LALIGN or BLAST. Preferably, BLAST is used to determine percent identity.

10 A factor possesses a "biological activity of GM-CSF" if it is capable of binding to any known GM-CSF receptor.

A "primary neurosphere" is a neurosphere generated by culturing brain tissue. Typically, the brain tissue is dissected and mechanically dissociated before being cultured  
15 in appropriate media and allowed to form neurospheres. Exemplary methods are described in, for instance, U.S. Patent No. 5,750,376.

A "secondary neurosphere" is a neurosphere generated by dissociating (passaging) a primary neurosphere and culturing the dissociated cells under conditions which result in  
20 the formation of neurospheres from single cells.

A "mammal" is any member in the mammalian family. A mammal is preferably a primate, rodent, feline, canine, domestic livestock (such as cattle, sheep, goats, horses, and pigs), and most preferably a human.  
25

A "demyelinating disease" is a disease or medical condition that is caused by or associated with demyelination. Examples of these diseases or conditions include multiple sclerosis (including the relapsing and chronic progressive forms of multiple sclerosis, acute multiple sclerosis, neuromyelitis optica (Devic's disease)), diffuse cerebral sclerosis  
30 (including Shilder's encephalitis periaxialis diffusa and Balo's concentric sclerosis). Demyelinating diseases also include a variety of diseases wherein demyelination is caused by viral infections, vaccines, and genetic disorders. Examples of these demyelinating diseases include acute disseminated encephalomyelitis (occurring after measles,

chickenpox, rubella, influenza or mumps; or after rabies or smallpox vaccination), necrotizing hemorrhagic encephalitis (including hemorrhagic leukoencephalitis), and leukodystrophies (including Krabbe's globboid leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, adrenomyeloneuropathy, adrenomyeloneuropathy, 5 Pelizaeus-Merzbacher leukodystrophy, Canavan's disease and Alexander's disease). The demyelinating disease is preferably multiple sclerosis or diffuse cerebral sclerosis, and most preferably multiple sclerosis.

10 "Treating or ameliorating" means the reduction or complete removal of the symptoms of a disease or medical condition.

An "effective amount" is an amount of a therapeutic agent sufficient to achieve the intended purpose. The effective amount of a given therapeutic agent will vary with factors such as the nature of the agent, the route of administration, the size and species of 15 the animal to receive the therapeutic agent, and the purpose of the administration. The effective amount in each individual case may be determined empirically by a skilled artisan according to established methods in the art.

## 20 Methods

Methods for the isolation and *in vitro* culture of multipotent neural stem cells have recently been developed (for example, see U.S. Patent Nos. 5,750,376; 5,980,885; 5,851,832). It was discovered that fetal brains can be used to isolate and culture multipotent neural stem cells *in vitro*. Moreover, in contrast to the long time belief that 25 adult brain cells are not capable of replicating or regenerating brain cells, it was found that neural stem cells may also be isolated from brains of adult mammals. These stem cells, either from fetal or adult brains, are capable of self-replicating. The progeny cells can again proliferate or differentiate into any cell in the neural cell lineage, including neurons, astrocytes and oligodendrocytes.

30 Most of the cells differentiated from neural stem cells are astrocytes. Therefore, although neural stem cells provide a good source of all kinds of mature or immature neural cells, using neural stem cells to produce oligodendrocytes for demyelinating diseases is

normally an inefficient process. The present invention, however, provides a method of significantly increasing the efficiency of oligodendrocyte production from neural stem cells. As shown in Example 1, when neural stem cells were allowed to differentiate in the presence of granulocyte-macrophage colony stimulating factor (GM-CSF), the percentage of oligodendrocytes increased by several folds. Therefore, GM-CSF can be used to enhance oligodendrocyte production from neural stem cells. In particular, GM-CSF can be used as a survival factor for oligodendrocytes or precursors thereof (Example 2).

GM-CSF does not stimulate neural stem cells to proliferate. In fact, inclusion of GM-CSF in the proliferation media of neural stem cells inhibited self-expansion of proliferated neural stem cells (Example 3), probably by inducing premature differentiation of neural stem cells. Indeed, the neural stem cells that were exposed to GM-CSF in the presence of proliferating signal (in this case, epidermal growth factor) expressed markers for oligodendrocyte progenitor cells shortly after being shifted to differentiation media, suggesting that these cells had committed to the oligodendrocyte lineage in the proliferation media. Consistent with these results, GM-CSF inhibited commitment to the neuronal lineage (Example 4).

The present invention thus provides a method of increasing oligodendrocyte production from neural stem cells by using an oligodendrocyte promoting factor, such as GM-CSF. Preferably, neural stem cells are first proliferated or expanded in the absence of the oligodendrocyte promoting factor, and the expanded population of neural stem cells are then incubated with the oligodendrocyte promoting factor to induce oligodendrocyte formation. Any agent capable of expanding neural stem cells can be used in this embodiment. These agents may stimulate proliferation, inhibit differentiation, or prevent cell death of neural stem cells. Exemplary agents include, without being limited to, epidermal growth factor (EGF), pituitary adenylate cyclase-activating polypeptide (PACAP), fibroblast growth factor (FGF), transforming growth factor  $\gamma$  (TGF $\gamma$ ), estrogen, ovarian hormone, prolactin, growth hormone, insulin-like growth factor, ciliary neurotrophic factor (CNTF) and bone morphogenetic protein (BMP). Additional agents may be identified by methods known in the art, such as adding a candidate agent to a culture of neural stem cells and assessing the number of neurospheres formed in the presence of the agent (see, e.g., U.S. Patent Nos. 5,750,376; 5,980,885; 5,851,832).



It should be noted that variants or analogs of these agents, which share a substantial identity with a native mammalian agent listed above and are capable of increasing neural stem cell numbers, can be used in the present application. For example, there are two forms of native mammalian PACAP, PACAP38 and PACAP27. Any variant or analog that is capable of increasing neural stem cell numbers and shares a substantial sequence identity with either PACAP38 or PACAP27 is suitable for use in the present invention. Particularly useful are the analogs and variants disclosed in, *e.g.*, U.S. Patent Nos. 5,128,242; 5,198,542; 5,208,320; 5,326,860; 5,623,050; 5,801,147 and 6,242,563.

Similarly, EGF variants or analogs, which share a substantial identity with a native mammalian EGF are capable of increasing neural stem cell numbers, can be used in the present application. These EGF variants and analogs include, but are not limited to, the recombinant modified EGF having a deletion of the two C-terminal amino acids and a neutral amino acid substitution at position 51, such as asparagine, glutamine, serine or alanine (particularly EGF51N or EGF51Q, having asparagine or glutamine at position 51, respectively; WO 03/040310), the EGF mutein (EGF-X<sub>16</sub>) in which the His residue at position 16 is replaced with a neutral or acidic amino acid (U.S. Patent No. 6,191,106), the 52-amino acid deletion mutant of EGF which lacks the amino terminal residue of the native EGF (EGF-D), the EGF deletion mutant in which the N-terminal residue as well as the two C-terminal residues (Arg-Leu) are deleted (EGF-B), the EGF-D in which the Met residue at position 21 is oxidized (EGF-C), the EGF-B in which the Met residue at position 21 is oxidized (EGF-A), heparin-binding EGF-like growth factor (HB-EGF), betacellulin, amphiregulin, neuregulin, or a fusion protein comprising any of the above. Other useful EGF analogs or variants are described in WO 03/040310, and U.S. Patent Nos. 6,191,106 and 5,547,935.

Specifically included as prolactins are the naturally occurring prolactin variants, prolactin-related protein, placental lactogens, S179D-human prolactin (Bernichtein et al., 2001), prolactins from various mammalian species, including but not limited to, human, other primates, rat, mouse, sheep, pig, and cattle, and the prolactin mutants described in U.S. Patent Nos. 6,429,186 and 5,955,346.

Alternatively, neural stem cells can be proliferated in the presence of the oligodendrocyte promoting factor to increase the number of committed oligodendrocyte progenitor cells before being allowed to differentiate.

5           The oligodendrocytes produced from neural stem cell culture can be introduced (e.g., by transplantation) into a mammal, particularly to compensate for lost or dysfunctional oligodendrocytes. The mammal is preferably a human, canine, feline, rodent, sheep, goat, cattle, horse, pig, or non-human primate. Most preferably, the mammal is human. Since neural stem cells can be cultured from brain tissues from mammals of any  
10       age, including adults, it is preferable to grow neural stem cells using a mammal's own tissue for autologous transplantation. Allogeneic and xenogeneic transplantations are also possible, particularly when the transplantation site is in the brain, where immunologic rejection is less severe due to the blood-brain barrier.

15           It is also contemplated that neural stem cells can be transplanted into a mammal and induced to form oligodendrocytes *in vivo*. Thus, neural stem cells may be expanded in culture using established methods, transplanted into the mammal, and contacted *in vivo* with the oligodendrocyte promoting factor to produce oligodendrocytes. Optionally, the transplanted neural stem cells can be expanded again *in vivo* by administering to the  
20       mammal a biological agent that is known to increase the number of neural stem cells as disclosed above.

          The cells are preferably introduced into the brain or spinal cord of the mammal, particularly at sites where oligodendrocytes are insufficient, for example, around axons that  
25       have been demyelinated. In humans, areas of demyelination are generally associated with plaque like structures, which can be visualized with magnetic resonance imaging (MRI). The cells may also be transplanted into other areas of the central nervous system, as glial cells are known to be able to migrate to their neuronal targets. A particular useful approach is to transplant into the "mirror image" location of a target lesion in the other hemisphere,  
30       since cells are known to efficiently migrate to the corresponding location in the opposite hemisphere through the corpus callosum (Learish et al., 1999).

The oligodendrocyte promoting factors or the biological agents can be administered by any suitable route established in the art, including, for example, intrathecally, intravascularly, intravenously, intramuscularly, intraperitoneally, transdermally, intradermally, subcutaneously, orally, topically, rectally, vaginally, nasally, or by inhalation. The route of administration depends primarily on the nature of the agent. For example, GM-CSF is capable of crossing the blood-brain barrier (McLay et al., 1997), hence it can be administered systemically as well as into the brain. The preferred method of administration is by injection (e.g., with a needle or a catheter) or infusion.

The present invention further provides a method of enhancing oligodendrocyte production *in vivo* by administering the oligodendrocyte promoting factor to a mammal under conditions that result in oligodendrocyte formation. The resultant oligodendrocytes are capable of remyelinating demyelinated neurons in the mammal, whereby demyelinating diseases in the mammal can be treated or ameliorated. Although previous researchers suggested that GM-CSF may enhance inflammation and degeneration of myelin (Be'eri et al., 1998; Ousman et al., 2001), our results indicate, unexpectedly, that GM-CSF is useful as an oligodendrocyte promoting factor.

It is contemplated that the present invention can also be used to prevent demyelinating diseases where a mammal is at risk of such diseases. Although the causes for multiple sclerosis are not entirely clear, certain risk factors have been identified. For example, multiple sclerosis (MS) occurs in 1-2% of first-degree relatives of MS patients, and people with certain histocompatibility antigens are correlated with MS as well. Therefore, the present invention may be used to prevent MS in the high-risk group.

The GM-CSF useful in the present invention includes any GM-CSF analog or variant that is capable of increasing oligodendrocyte production from neural stem cells. A GM-CSF analog or variant is a polypeptide which contains at least about 30% of the amino acid sequence of the native human GM-CSF, and which possesses a biological activity of GM-CSF. Preferably, the biological activity of GM-CSF is the ability to bind a GM-CSF receptor. Specifically included as GM-CSFs are the naturally occurring GM-CSF proteins and GM-CSFs from various species, including but not limited to, human, canine, feline, rodent, sheep, goat, cattle, equine, swine, or non-human primates.

Besides GM-CSF, other cytokines that have similar biological functions can also be used in lieu of or in addition to GM-CSF as an oligodendrocyte promoting factor in the present invention. These cytokines include granulocyte colony stimulating factor (G-CSF), interleukin-3 (IL-3) and interleukin-5 (IL-5). As with GM-CSF, analogs and variants of G-CSF, IL-3 and IL-5 can also be employed. These G-CSF, IL-3 and IL-5 analogs and variants should share substantial sequence identity with the native human G-CSF, IL-3 and IL-5, respectively, and bind a receptor for G-CSF, IL-3 and IL-5, respectively. The ability of each analog and variant to stimulate production of oligodendrocyte can be determined according to the methods disclosed herein. It is further contemplated that factors known to induce or activate GM-CSF, G-CSF, IL-3 and IL-5 can be employed to promote oligodendrocyte formation and remyelination in accordance with the present disclosure.

In addition to the oligodendrocyte promoting factors described above, other factors known to enhance oligodendrocyte differentiation (see, e.g., Miller, 2002) can be used in combination with the oligodendrocyte promoting factor(s). These other factors include, without being limited to, Sonic hedgehog, platelet derived growth factor (PDGF), ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), triiodothyronine (T3), cAMP and retinoic acid. Furthermore, factors that have mitogenic, proliferative or survival effects on oligodendrocytes can also be added, such as neurotrophin 3 (NT-3), growth-related oncogene alpha (GRO-alpha), neuregulin and/or EGF. As with all other factors and agents in the present invention, analogs and variants of these factors that share a substantial sequence identity and the desired biological activity can also be used.

The following examples are offered to illustrate this invention and are not to be construed in any way as limiting the scope of the present invention.

## EXAMPLES

In the examples below, the following abbreviations have the following meanings.  
Abbreviations not defined have their generally accepted meanings.

5	$^{\circ}\text{C}$	=	degree Celsius
	hr	=	hour
	min	=	minute
	$\mu\text{M}$	=	micromolar
	mM	=	millimolar
10	M	=	molar
	ml	=	milliliter
	$\mu\text{l}$	=	microliter
	mg	=	milligram
	$\mu\text{g}$	=	microgram
15	FBS	=	fetal bovine serum
	PBS	=	phosphate buffered saline
	DMEM	=	Dulbecco's modified Eagle's medium
	$\nabla$ -MEM	=	$\nabla$ -modified Eagle's medium
	MHM	=	media hormone mix
20	GM-CSF	=	granulocyte-macrophage colony stimulating factor
	G-CSF	=	granulocyte colony stimulating factor
	IL-3	=	interleukin 3
	IL-5	=	interleukin 5
	EGF	=	epidermal growth factor
25	PDGF	=	platelet derived growth factor
	GalC	=	galactocerebroside
	MBP	=	myelin basic protein
	T3	=	triiodothyronine
	CNTF	=	ciliary neurotrophic factor
30	DIV	=	days <i>in vitro</i>

**EXAMPLE 1****GM-CSF enhances oligodendrocyte production from neural stem cells**

To determine the effect of GM-CSF on neural stem cell differentiation, a culture of neural stem cells was prepared from mouse embryos and subjected to a rapid differentiation protocol. Embryonic Day 14 (E14) mouse ganglionic eminence was dissected and grown in media hormone mix (MHM) plus 20 ng/ml epidermal growth factor (EGF) for one week to generate primary neurospheres. The composition of MHM was as follows:

DMEM/F12 (1:1)  
glucose (0.6%)  
glutamine (2 mM)  
sodium bicarbonate (3 mM)  
HEPES (5 mM)  
insulin (25  $\mu$ g/ml)  
transferrin (100  $\mu$ g/ml)  
progesterone (20 nM)  
putrescine (60  $\mu$ M)  
selenium chloride (30 nM)

Primary neurospheres were then dissociated and plated on poly-L-ornithine coated coverslips in 24-well plates at a density of 200,000 cells/ml in 1 ml of MHM per well. Cells were allowed to differentiate in the absence or presence of 20 ng/ml GM-CSF (murine recombinant GM-CSF, Peprotech) in MHM, or 20 ng/ml of triiodothyronine (T3, Sigma) in MHM, or in a combination of both GM-CSF and T3. T3 is a known oligodendrocyte differentiation factor, which was used to compare GM-CSF in these experiments.

After 1, 3 or 5 days, the cells were fixed with 4% paraformaldehyde. The cells fixed after 1, 3 and 5 days were immunostained for the immature oligodendrocyte marker O4, the maturing oligodendrocyte marker galactocerebroside (GalC), and the mature oligodendrocyte marker myelin basic protein (MBP), respectively. After staining, the numbers of O4-positive, GalC-positive and MBP-positive cells were counted. The total

number of cells were determined using Hoechst staining and live nuclei morphology under 40X magnification. This experiment was performed four times, and 10 non-overlapping fields per coverslip were counted each time. Statistical analyses of the results were performed using Anova with a Tukey-Honest post-hocs analysis. The results are shown in

5 Table 1.

**Table 1. The Effect of GM-CSF on neural stem cell differentiation**

Antigen	DIV	Control	GM-CSF	T3	GM-CSF+T3
% positive cells					
O4	1	10.3±0.8	16.6±1.2*	18.2±1.2*	23.3±2.0* †
O4	3	20.9±1.27	25.7±1.5	35.9±1.7*	42.5±2.3* †
O4	5	7.3±0.9	9.6±1.0	19.9±1.5*	46.2±2.67* †
GalC	1	2.1±0.4	4.1±0.6	8.0±0.8*	4.7±0.9*
GalC	3	5.2±0.6	7.4±0.8	15.3±1.5*	10.4±1.4*
GalC	5	3.6±0.6	7.9±1.0*	11.1±0.9*	9.6±1.1*
MBP	1	0.8±0.2	1.2±0.3	1.6±0.4	1.0±0.3
MBP	3	2.4±0.5	8.1±0.9*	13.9±1.1*	14.1±1.1*
MBP	5	2.0±0.5	12.2±1.3*	17.2±1.6*	16.3±1.7*

(\* p<0.05 as compared to control, † p<0.05 as compared to GM-CSF and T3)

10 Therefore, GM-CSF significantly increased the percentage of oligodendrocytes in every stage of oligodendrocyte development, indicating that GM-CSF can be used to produce oligodendrocytes more efficiently. Other oligodendrocyte differentiation factors, such as T3, can be optionally employed in combination with GM-CSF.

15 The effect of GM-CSF was specifically inhibited by GM-CSF receptor alpha (sGMRa), a soluble factor that binds GM-CSF. A rapid differentiation protocol was performed, as described above, in the absence or presence of GM-CSF, with or without a 100-fold excess of sGMRa. After 5 days *in vitro*, the cells were fixed, immunostained with the mature oligodendrocyte marker MBP and counted as previously described. The results  
20 are shown in Figure 1, which indicates that the effect of GM-CSF was specific.

## EXAMPLE 2

### Effect of GM-CSF on oligodendrocyte survival

5           The survival effects of GM-CSF on oligodendrocytes were examined with two lines of experiments. In the first line of experiments, neural stem cells were cultured as described in Example 1 in the presence or absence of GM-CSF or T3, and were fixed after 1, 3 or 5 days of culture in differentiation media. The fixed cells were immunostained for the maturing oligodendrocyte marker GalC and TUNEL, which is a marker of dying cells.

10       The numbers of dying, maturing oligodendrocytes (GalC+, TUNEL+ cells) were then counted and their percentage in total GalC+ cells are shown in Figure 2.

          As shown in Figure 2, GM-CSF significantly reduced the number of dying GalC+ cells, while T3 had only minor survival effects, if any. This survival effect of GM-CSF

15       was evident after the cells had been in differentiation culture for only one day, and became more prominent with time. Therefore, these results indicate that GM-CSF can act as a survival factor for oligodendrocytes.

          In the second line of experiments, GM-CSF was given to differentiating neural

20       stem cells at different times. Thus, neural stem cell culture was placed in differentiation media as described in Example 1, and GM-CSF was added after 24 or 48 hours, or added in the beginning but removed after 24 or 48 hours. Similarly, T3 was added or removed in the same manner in parallel experiments. The cells were fixed after 5 days *in vitro* and immunostained with the mature oligodendrocyte marker MBP. The experiments were

25       performed 4 times (N=4) and the results are shown in Table 2 (\*p<0.05).



**Table 2. Survival Assay**

Condition	MBP+ cells after 5DIV
Control	2.8±0.3
GM-CSF added after 24 hours	8.1±0.9
GM-CSF added after 48 hours	3.9±0.6
	]
	*
GM-CSF removed after 24 hours	5.4±1.0
GM-CSF removed after 48 hours	9.7±1.0
	]
	*
GM-CSF present for 5 DIV	8.0±0.8
T3 added after 24 hours	14.8±1.5
T3 added after 48 hours	12.0±1.1
T3 removed after 24 hours	15.5±1.1
T3 removed after 48 hours	13.8±1.1
T3 present for 5 DIV	13.9±1.1

Therefore, the presence of GM-CSF is required for an extended period of time in order to have an effect on oligodendrocyte numbers, indicating that GM-CSF enhances survival of oligodendrocytes or precursors thereof. In contrast, the results indicate that T3 acts as a differentiation factor because the number of oligodendrocytes did not change regardless of the length of time T3 was present in the culture.

Taken together, both lines of experiments indicate that GM-CSF is capable of enhancing survival of oligodendrocytes or precursors thereof.

### EXAMPLE 3

#### *Effect of GM-CSF during stem cell proliferation*

To assess the effect of GM-CSF on proliferation of neural stem cells, the number of cells generated in neurosphere cultures, prepared according to Example 1, was counted when grown for 1 week in various culture media. Thus, E14 ganglionic eminence cells were grown at a density of 200,000 cells/ml in 40 ml of media for 1 week. The media were MHM plus EGF, MHM plus EGF and GM-CSF, or MHM plus EGF and T3. Spheres were then collected, dissociated and cells were counted with a hemacytometer. The cell numbers were calculated as percentages of the control (MHM plus EGF).

As shown in Figure 3, these results indicate that GM-CSF slightly increased the total cell number in the neural stem cell culture while T3 reduces the number.

The effect of GM-CSF on primary neurosphere numbers was also examined by growing cells from E14 mouse ganglionic eminence in MHM plus EGF, MHM plus EGF plus GM-CSF, or MHM plus EGF plus T3, all at concentrations of 20 ng/ml. Thus, E14 mouse ganglionic eminence cells were dissociated and plated in 96-well plates at a density of 10,000 cells/ml in 200  $\mu$ l of media per well, and allowed to form primary neurospheres for a week. The number of primary spheres in each well was then counted and the aforementioned statistical analysis was performed.

The results, shown in Figure 4, suggest that neither GM-CSF nor T3 have significant effects on the ability of neural stem cells to form primary neurospheres.

Furthermore, the effect of GM-CSF on self-expansion, proliferation of secondary neurospheres derived from primary neurospheres, was also assessed. Three media were used in the preparation of primary spheres: MHM plus EGF, MHM plus EGF plus  
5 GM-CSF and MHM plus EGF plus T3. The primary spheres were dissociated, plated in 96-well plates at a concentration of 1000 cells/well in 200  $\mu$ L media per well, and allowed to form secondary neurospheres for a week. The media for secondary cultures consisted of MHM plus EGF alone, MHM plus GM-CSF or T3 alone, or MHM plus EGF supplemented with GM-CSF or T3. The number of secondary spheres in each well was then counted,  
10 calculated as percentage of control (EGF to EGF).

Figure 5 shows that GM-CSF does not significantly affect the number of secondary neurospheres derived from EGF-responsive neural stem cells. In addition, T3 decreased the number of secondary neurospheres in this experiment, possibly by enhancing  
15 differentiation. The results also indicate that including GM-CSF or T3 in the media for primary neurospheres was detrimental to formation of secondary spheres.

Taken together, these results indicate that GM-CSF does not enhance proliferation or self-expansion of neural stem cells. The increase by GM-CSF of the number of total  
20 cells in primary culture may be due to the survival effect of GM-CSF.

#### EXAMPLE 4

##### Effect of GM-CSF on fate determination of neural stem cells

To determine if the presence of GM-CSF during primary neurosphere formation impacts fate determination of neural stem cells, primary neurospheres were generated in either EGF alone, EGF plus GM-CSF, or EGF plus T3 as described in Example 3. The primary spheres were then dissociated and plated on poly-L-ornithine coated coverslips in 24-well plates at a density of 200,000 cells/well in 1 ml of MHM per well, and allowed to  
25 differentiate for 5 days. At the end the differentiation period, the cells were fixed with 4% paraformaldehyde and immunostained for the mature oligodendrocyte marker MBP, the neuronal marker  $\beta$ -tubulin, and Hoechst. The total number of live cells, evidenced by  
30

Hoechst stain, were counted as well as the immunostained cells. The results are shown in Figure 6.

As shown in Figure 6, GM-CSF and T3 increased the number of mature  
5 oligodendrocytes and decreased that of neurons. In conjunction with the previous  
examples, these results indicate that GM-CSF promotes differentiation of oligodendrocytes  
from neural stem cells and reduces the number of neuronal progenitors, thereby reducing  
the number of neurons. Therefore, GM-CSF can be used to produce oligodendrocytes by  
shifting the fate of neural stem cells toward the oligodendrocyte lineage.

10

We claim:

1. A method of producing oligodendrocytes from mammalian multipotent neural stem cells, comprising contacting multipotent neural stem cells with an effective  
5 amount of at least one oligodendrocyte promoting factor under conditions that result in production of oligodendrocytes from the multipotent neural stem cells, wherein the oligodendrocyte promoting factor is selected from the group consisting of granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), interleukin 3 (IL-3) and  
10 interleukin 5 (IL-5).
2. The method of claim 1 wherein the oligodendrocyte promoting factor is GM-CSF or G-CSF.
- 15 3. The method of claim 1 wherein the oligodendrocyte promoting factor is GM-CSF.
4. The method of claim 1 further comprising contacting the multipotent neural stem cells with triiodothyronine.
- 20 5. The method of claim 1 wherein the multipotent neural stem cells are provided as a cell culture.
6. The method of claim 5 wherein the cell culture is prepared using mammalian brain tissue.
- 25 7. The method of claim 6 wherein the mammalian brain tissue is obtained from a non-embryonic mammal.
8. The method of claim 6 wherein the mammalian brain tissue is obtained from an  
30 adult mammal.
9. The method of claim 6 wherein the brain tissue is obtained from the subventricular zone.

10. The method of claim 1 wherein the multipotent neural stem cells are located in a mammal.
- 5 11. The method of claim 10 wherein the multipotent neural stem cells are located in the subventricular zone of the mammal.
12. The method of claim 1 wherein the multipotent neural stem cells are selected from the group consisting of human, dog, cat, rodent, sheep, goat, cattle, horse, pig, and non-human primate cells.
- 10 13. The method of claim 1 wherein the multipotent neural stem cells are human cells.
14. The method of claim 1 further comprising contacting the multipotent neural stem cells with an effective amount of at least one biological agent that is capable of increasing the number of multipotent neural stem cells.
- 15 15. The method of claim 14 wherein the biological agent is selected from the group consisting of epidermal growth factor (EGF), fibroblast growth factor (FGF), pituitary adenylate cyclase-activating polypeptide (PACAP), transforming growth factor  $\gamma$  (TGF $\gamma$ ), ciliary neurotrophic factor (CNTF), estrogen, ovarian hormone, prolactin, growth hormone, and insulin-like growth factor 1.
- 20 16. The method of claim 14 wherein the biological agent is EGF51N.
- 25 17. The method of claim 14 wherein the multipotent neural stem cells are contacted with the oligodendrocyte promoting factor and the biological agent concurrently.
18. The method of claim 14 wherein the multipotent neural stem cells are contacted with the biological agent prior to the oligodendrocyte promoting factor.
- 30 19. A composition comprising the oligodendrocytes produced by the method of claim 4.

20. The composition of claim 19 further comprising a pharmaceutically acceptable excipient and/or a pharmaceutically acceptable carrier.
- 5 21. A method of providing oligodendrocytes to a mammal, comprising  
(a) introducing multipotent neural stem cells into the mammal and  
administering an effective amount of at least one oligodendrocyte promoting  
factor to the mammal under conditions that result in oligodendrocyte formation  
from the neural stem cells; or  
10 (b) introducing into the mammal an effective amount of the composition of  
claim 20.
22. The method of claim 21(a) further comprising contacting the neural stem cells  
with an effective amount of at least one biological agent that is capable of  
15 increasing the number of neural stem cells.
23. The method of claim 22 wherein the neural stem cells are contacted with the  
biological agent prior to being introduced into the mammal.
- 20 24. The method of claim 22 wherein the biological agent is selected from the group  
consisting of epidermal growth factor (EGF), pituitary adenylate cyclase-  
activating polypeptide (PACAP), fibroblast growth factor (FGF), transforming  
growth factor  $\gamma$  (TGF $\gamma$ ), ciliary neurotrophic factor (CNTF), estrogen, prolactin,  
growth hormone, and insulin-like growth factor 1.  
25
25. The method of claim 22 wherein the biological agent is EGF51N.
26. The method of claim 21(a) further comprising contacting the multipotent neural  
stem cells with triiodothyronine.  
30
27. The method of claim 21 wherein the mammal suffers from a demyelinating  
disease.

28. The method of claim 27 wherein the demyelinating disease is selected from the group consisting of multiple sclerosis, acute disseminated encephalomyelitis, diffuse cerebral sclerosis, necrotizing hemorrhagic encephalitis and leukodystrophies.
29. The method of claim 27 wherein the demyelinating disease is multiple sclerosis.
30. The method of claim 21 wherein the mammal is human.
31. A method of treating or ameliorating a demyelinating disease in a mammal, comprising administering to the mammal an effective amount of at least one oligodendrocyte promoting factor, wherein the oligodendrocyte promoting factor is selected from the group consisting of granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), interleukin 3 (IL-3) and interleukin 5 (IL-5).
32. The method of claim 31 wherein the oligodendrocyte promoting factor is administered into a ventricle in the brain of the mammal.
33. The method of claim 31 wherein the oligodendrocyte promoting factor is administered into the lateral ventricle of the mammal.
34. The method of claim 31 further comprising administering to the mammal an effective amount of at least one biological agent capable of increasing the number of neural stem cells.
35. The method of claim 34 wherein the biological agent is selected from the group consisting of epidermal growth factor (EGF), pituitary adenylate cyclase-activating polypeptide (PACAP), fibroblast growth factor (FGF), transforming growth factor  $\gamma$  (TGF $\gamma$ ), ciliary neurotrophic factor (CNTF), estrogen, ovarian hormone, prolactin, growth hormone, and insulin-like growth factor 1.



36. The method of claim 34 wherein the biological agent is EGF51N.
37. The method of claim 31 further comprising administering triiodothyronine to the mammal.
- 5 38. The method of claim 31 wherein the demyelinating disease is selected from the group consisting of multiple sclerosis, acute disseminated encephalomyelitis, diffuse cerebral sclerosis, necrotizing hemorrhagic encephalitis and leukodystrophies.
- 10 39. The method of claim 31 wherein the demyelinating disease is multiple sclerosis.
40. The method of claim 31 wherein the mammal is human.

15

1/6






Figure 1


2 / 6

**Figure 2**


3 / 6

**Figure 3**


4 / 6

**Figure 4**

5 / 6

**Figure 5**

6 / 6

**Figure 6**

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number  
WO 2004/011632 A3

(51) International Patent Classification<sup>7</sup>: C12N 5/08,  
A61K 38/19, 38/20, A51K 35/30, A61P 25/00

(21) International Application Number:  
PCT/CA2003/001151

(22) International Filing Date: 30 July 2003 (30.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/399,192 30 July 2002 (30.07.2002) US

(71) Applicant (for all designated States except US): STEM  
CELL THERAPEUTICS INC. [CA/CA]; 415 Yonge  
Street, Suite 1103, Toronto, Ontario M5B 2H7 (CA).

(72) Inventor; and

(75) Inventor/Applicant (for US only): WEISS, Samuel  
[CA/CA]; 4540 Chapel Road, N.W., Calgary, Alberta T2L  
1A6 (CA).

(74) Agents: TORYS LLP et al.; Maritime Life Tower, Suite  
3000, 79 Wellington St. W., Box 270, TD Centre, Toronto,  
Ontario M5K 1N2 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the International search report:  
15 April 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: OLIGODENDROCYTE PRODUCTION FROM MULTIPOTENT NEURAL STEM CELLS

(57) Abstract: This invention relates to methods of producing oligodendrocytes from multipotent neural stem cells by using at least one oligodendrocyte promoting factor, particularly granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin 3 or interleukin 5. The neural stem cells may optionally be expanded prior to being subjected to the oligodendrocyte promoting factor.



## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/CA 03/01151

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N5/08 A61K38/19 A61K38/20 A51K35/30 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 10292 A (NEUROSPHERES) 11 May 1994 (1994-05-11) page 23 -page 25	1,19,21
X	MEHLER M F ET AL: "Cytokines regulate the cellular phenotype of developing neural lineage species." INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY FOR DEVELOPMENTAL NEUROSCIENCE. 1995 JUN-JUL, vol. 13, no. 3-4, June 1995 (1995-06), pages 213-240, XP002267006 ISSN: 0736-5748 the whole document	1-3

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 January 2004

Date of mailing of the international search report

19/02/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Moreau, J

## INTERNATIONAL SEARCH REPORT

National Application No

PCT/CA 03/01151

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>MCQUALTER J L ET AL: "Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis."  THE JOURNAL OF EXPERIMENTAL MEDICINE. 1 OCT 2001,  vol. 194, no. 7,  1 October 2001 (2001-10-01), pages 873-881, XP002267007  ISSN: 0022-1007  the whole document</p>	31
A	<p>WO 96 15226 A (NEUROSPHERES HOLDING)  23 May 1996 (1996-05-23)  the whole document</p>	1-40
A	<p>GAGE F H: "Mammalian neural stem cells" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US,  vol. 287, no. 5457,  25 February 2000 (2000-02-25), pages 1433-1438, XP002220467  ISSN: 0036-8075  the whole document</p>	1-40
A	<p>KOHAMA I ET AL: "Transplantation of cryopreserved adult human Schwann cells enhances axonal conduction in demyelinated spinal cord."  THE JOURNAL OF NEUROSCIENCE : THE OFFICIAL JOURNAL OF THE SOCIETY FOR NEUROSCIENCE. 1 FEB 2001,  vol. 21, no. 3,  1 February 2001 (2001-02-01), pages 944-950, XP002267008  ISSN: 1529-2401  the whole document</p>	1-40

-/-

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/CA 03/01151

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2002 DUBOIS T M ET. AL: "GRANULOCYTE MACROPHAGE - COLONY STIMULATING FACTOR ( GM - CSF ) IS A FATE DETERMINATION AND DIFFERENTIATION FACTOR FOR NEURAL STEM CELL - GENERATED OLIGODENDROCYTE PRECURSORS ( OLPS )." Database accession no. PREV200300293880 XP002267009 abstract &amp; SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2002, 2002, pages Abstract No. 329.12 URL-http://sf, 32ND ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE; ORLANDO, FLORIDA, USA; NOVEMBER 02-07, 2002 -----</p>	1-40

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA 03/01151

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 21-40 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Patent Application No

PCT/CA 03/01151

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9410292	A	11-05-1994	AT 234353 T 15-03-2003
			AU 703729 B2 01-04-1999
			AU 4924197 A 12-03-1998
			AU 5367694 A 24-05-1994
			CA 2148138 A1 11-05-1994
			WO 9410292 A1 11-05-1994
			DE 69332759 D1 17-04-2003
			DE 69332759 T2 16-10-2003
			DK 669973 T3 14-07-2003
			EP 1298202 A2 02-04-2003
			EP 0669973 A1 06-09-1995
			ES 2194016 T3 16-11-2003
			FI 952022 A 27-04-1995
			JP 8502652 T 26-03-1996
			NO 951617 A 27-04-1995
			PT 669973 T 30-06-2003
			WO 9416718 A1 04-08-1994
			US 2003082515 A1 01-05-2003
			US 2003109008 A1 12-06-2003
			US 2003095956 A1 22-05-2003
			US 6071889 A 06-06-2000
			US 5750376 A 12-05-1998
			US 6399369 B1 04-06-2002
			US 6294346 B1 25-09-2001
			US 5980885 A 09-11-1999
			US 6497872 B1 24-12-2002
			US 5851832 A 22-12-1998
			US 2003049837 A1 13-03-2003
WO 9615226	A	23-05-1996	AU 716811 B2 09-03-2000
			AU 3836795 A 06-06-1996
			CA 2204630 A1 23-05-1996
			WO 9615226 A1 23-05-1996
			CN 1170435 A 14-01-1998
			EP 0792350 A1 03-09-1997
			FI 971956 A 04-07-1997
			JP 10509592 T 22-09-1998
			NO 972171 A 07-07-1997
			US 2003082515 A1 01-05-2003
			US 2003109008 A1 12-06-2003
			US 2003095956 A1 22-05-2003
			US 6071889 A 06-06-2000
			US 5750376 A 12-05-1998
			US 6399369 B1 04-06-2002
			US 6294346 B1 25-09-2001
			US 5980885 A 09-11-1999
			US 6497872 B1 24-12-2002
			US 5851832 A 22-12-1998
			US 2003049837 A1 13-03-2003